News
TCRX
7.80
-2.62%
-0.21
TSCAN THERAPEUTICS INC - ON-TRACK TO REPORT INITIAL DATA FROM SOLID TUMOR CLINICAL TRIAL IN 2024
Reuters · 1d ago
Weekly Report: what happened at TCRX last week (0429-0503)?
Weekly Report · 4d ago
Tscan Therapeutics, Inc.: Initial statement of beneficial ownership of securities
Press release · 05/03 07:39
Weekly Report: what happened at TCRX last week (0422-0426)?
Weekly Report · 04/29 10:01
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
TScan Therapeutics, Inc. Is a clinical-stage biopharmaceutical company focused on the development of T cell therapies for the treatment of cancer. The underwriters of its previously announced public offering have partially exercised their over-allotment option to purchase additional shares.
Barchart · 04/24 10:03
Tscan Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
Press release · 04/24 00:20
Unveiling 4 Analyst Insights On TScan Therapeutics
TScan Therapeutics underwent analysis by 4 analysts in the last quarter. The company is a biopharmaceutical company focused on the development of cancer treatments. The average price target for TScanTherapeutics is $10.75 and the company's 12-month revenue growth rate is 132.99%. The company has an impressive financial performance.
Benzinga · 04/23 18:01
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Benzinga · 04/23 17:17
TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 27TH ANNUAL MEETING
Reuters · 04/22 21:01
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
Simplify Propel Opportunities ETF (SURI) is a healthcare-based fund that provides exposure to global fixed-income and equity markets in the healthcare sector. The fund offers a near-13% yield from its distributions. SURI has a since-inception return of -13%, but its recent performance has shown potential for growth.
Seeking Alpha · 04/22 15:18
Weekly Report: what happened at TCRX last week (0415-0419)?
Weekly Report · 04/22 09:57
TSCAN THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING
Reuters · 04/19 14:05
Tscan Therapeutics, Inc.: Prospectus [Rule 424(b)(5)]
Press release · 04/18 10:50
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
TipRanks · 04/18 09:32
BUZZ-TScan Therapeutics rises after upsized $150 mln stock offering
Shares of TScan Therapeutics up 2.4% at $7.30 premarket after upsized $150 mln stock offering. Cancer-focused firm announces 21.1 mln shares, including pre-funded warrants. Offering size boosted from $125 mln and priced in-line with target.
Reuters · 04/17 13:10
TScan Therapeutics prices upsized stock offering to raise $150 million
Seeking Alpha · 04/17 07:37
TScan Therapeutics Prices Upsized $150M Public Offering 2,472,581 Common Shares At $7.13/Share
TScan Therapeutics announces pricing of an underwritten public offering of 2,472,581 shares of its voting common stock. The company says the offering price is equal to the closing price of the company's stock on April 16, 2024. The firm also plans to issue warrants to buy the shares.
Benzinga · 04/17 06:13
TScan Therapeutics Announces Pricing Of Public Offering - Quick Facts
NASDAQ · 04/17 05:36
*TScan Therapeutics Plans to Use Proceeds for General Corporate Purposes >TCRX
Dow Jones · 04/17 05:18
*TScan Therapeutics Prices Upsized $150M Public Offering of Common Stock, Warrants >TCRX
Dow Jones · 04/17 05:18
More
Webull provides a variety of real-time TCRX stock news. You can receive the latest news about Tscan Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.